Immunomodulation and allogeneic blood transfusion

Transfusion Alternatives in Transfusion Medicine

Volumn 10, Issue 3, 2008, Pages 127-138

  Waanders, Marloes ^a,b   Van De Watering, Leo ^b   Brand, Anneke ^a,b  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Sanquin Bloedbank Regio Zuidwest Rotterdam   (Netherlands)

Author keywords

Blood transfusion; Cancer surveillance; Immunomodulation; Infection; Leukocytes; Transplantation tolerance

Indexed keywords

ADAPTIVE IMMUNITY; ALLOTRANSPLANTATION; ANTIGEN DETECTION; ANTIGEN EXPRESSION; ARTICLE; BLOOD FILTRATION; BLOOD TRANSFUSION REACTION; CANCER EPIDEMIOLOGY; CELLULAR IMMUNITY; CLINICAL RESEARCH; CLINICAL TRIAL; GRAFT SURVIVAL; HEMORRHAGIC SHOCK; HOSPITAL INFECTION; HUMAN; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; IN VITRO STUDY; INNATE IMMUNITY; LEUKAPHERESIS; MICROBIAL CONTAMINATION; MULTIPLE ORGAN FAILURE; OBSERVATIONAL STUDY; POSTOPERATIVE INFECTION; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; SURGICAL MORTALITY; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; TUMOR IMMUNITY;

EID: 65249158561     PISSN: 12959022     EISSN: 1778428X     Source Type: Journal    
DOI: 10.1111/j.1778-428X.2008.00114.x     Document Type: Article

References (109)

1. Brittingham TE, Chaplin H, Jr. Febrile transfusion reactions caused by sensitivity to donor leukocytes and platelets. JAMA 1957; 165: 819-25.
2. Ward HN. Pulmonary infiltrates associated with leukoagglutinin transfusion reactions. Ann Intern Med 1970; 73: 689-94.
3. Yankee RA, Graff KS, Dowling R, Henderson ES. Selection of unrelated compatible platelet donors by lymphocyte HL-A matching. N Engl J Med 1973; 288: 760-4.
4. The TRAP Study Group. Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions. The Trial to Reduce Alloimmunization to Platelets Study Group. N Engl J Med 1997; 337: 1861-9.
5. Opelz G, Sengar DP, Mickey MR, Terasaki PI. Effect of blood transfusions on subsequent kidney transplants. Transplant Proc 1973; 5: 253-9.
6. Gantt CL. Red blood cells for cancer patients. Lancet 1981; 2: 363.
7. Dzik S, Mincheff M, Puppo F. Apoptosis, transforming growth factor-beta, and the immunosuppressive effect of transfusion. Transfusion 2002; 42: 1221-3.
8. Muylle L. The role of cytokines in blood transfusion reactions. Blood Rev 1995; 9: 77-83.
9. Heddle NM, Klama L, Singer J, et al. The role of the plasma from platelet concentrates in transfusion reactions. N Engl J Med 1994; 331: 625-8.
10. Izbicki G, Rudensky B, Na'amad M, et al. Transfusion-related leukocytosis in critically ill patients. Crit Care Med 2004; 32: 439-42.
11. Chang H, Voralia M, Bali M, Sher GD, Branch DR. Irreversible loss of donor blood leucocyte activation may explain a paucity of transfusion-associated graft-versus-host disease from stored blood. Br J Haematol 2000; 111: 146-56.
12. Mincheff MS, Meryman HT, Kapoor V, Alsop P, Wotzel M. Blood transfusion and immunomodulation: A possible mechanism. Vox Sang 1993; 65: 18-24.
13. Schechter GP, Whang-Peng J, McFarland W. Circulation of donor lymphocytes after blood transfusion in man. Blood 1977; 49: 651-6.
14. Vervoordeldonk SF, Doumaid K, Remmerswaal EB, et al. Long-term detection of microchimaerism in peripheral blood after pretransplantation blood transfusion. Br J Haematol 1998; 102: 1004-9.
15. Lee TH, Paglieroni T, Utter GH, et al. High-level long-term white blood cell microchimerism after transfusion of leukoreduced blood components to patients resuscitated after severe traumatic injury. Transfusion 2005; 45: 1280-90.
16. Persijn GG, Cohen B, Lansbergen Q, van Rood JJ. Retrospective and prospective studies on the effect of blood transfusions in renal transplantation in The Netherlands. Transplantation 1979; 28: 396-401.
17. Lazda VA, Pollak R, Mozes MF, Barber PL, Jonasson O. Evidence that HLA class II disparity is required for the induction of renal allograft enhancement by donor-specific blood transfusions in man. Transplantation 1990; 49: 1084-7.
18. Lagaaij EL, Hennemann IP, Ruigrok M, et al. Effect of one-HLA-DR-antigen-matched and completely HLA-DR-mismatched blood transfusions on survival of heart and kidney allografts. N Engl J Med 1989; 321: 701-5.
19. Hiesse C, Busson M, Buisson C, et al. Multicenter trial of one HLA-DR-matched or mismatched blood transfusion prior to cadaveric renal transplantation. Kidney Int 2001; 60: 341-9.
20. Opelz G, Vanrenterghem Y, Kirste G, et al. Prospective evaluation of pretransplant blood transfusions in cadaver kidney recipients. Transplantation 1997; 63: 964-7.
21. Alexander JW, Babcock GF, First MR, et al. The induction of immunologic hyporesponsiveness by preoperative donor-specific transfusions and cyclosporine in human cadaveric transplants. A preliminary trial. Transplantation 1992; 53: 423-7.
22. Sanfilippo FP, Bollinger RR, MacQueen JM, Brooks BJ, Koepke JA. A randomized study comparing leukocyte-depleted versus packed red cell transfusions in prospective cadaver renal allograft recipients. Transfusion 1985; 25: 116-19.
23. Lundgren G, Groth CG, Albrechtsen D, et al. HLA-matching and pretransplant blood transfusions in cadaveric renal transplantation - a changing picture with cyclosporin. Lancet 1986; 2: 66-9.
24. Melzer JS, Husing RM, Feduska NJ, et al. The beneficial effect of pretransplant blood transfusions in cyclosporine-treated cadaver renal allograft recipients. Transplantation 1987; 43: 61-4.
25. Kerman RH, Van Buren CT, Lewis RM, Kahan BD. Successful transplantation of 100 untransfused cyclosporine-treated primary recipients of cadaveric renal allografts. Transplantation 1988; 45: 37-40.
26. Iwaki Y, Cecka JM, Terasaki PI. The transfusion effect in cadaver kidney transplants - yes or no. Transplantation 1990; 49: 56-9.
27. Middleton D, Martin J, Douglas J, McClelland M. Transfusion of one HLA-DR antigen-matched blood to potential recipients of a renal allograft. Transplantation 1994; 58: 845-8.
28. Bayle F, Masson D, Zaoui P, et al. A haplo-identical transfusion in first renal allograft recipients: Effect on alloimmunisation, acute rejection episodes, and graft survival. Transplant Proc 1995; 27: 2457-8.
29. Christiaans MH, van Hooff JP, Nieman F, van den Berg-Loonen EM. HLA-DR matched transfusions: Development of donor-specific T- and B-cell antibodies and renal allograft outcome. Transplantation 1999; 67: 1029-35.
30. Mariat C, Alamartine E, De Filippis JP, et al. Effect of HLA semi-identical pretransplant blood transfusions on renal allograft outcome. Transplant Proc 2000; 32: 381-3.
31. Keogh A, Baron DW, Spratt P, Esmore D, Chang V. The effect of blood pretransfusion on orthotopic cardiac transplantation. Transplant Proc 1987; 19: 2845-6.
32. Katz MR, Barnhart GR, Goldman MH, et al. Pretransplant transfusions in cardiac allograft recipients. Transplantation 1987; 43: 499-501.
33. Kerman RH, Van Buren CT, Lewis RM, et al. The impact of HLA A, B, and DR blood transfusions and immune responder status on cardiac allograft recipients treated with cyclosporine. Transplantation 1988; 45: 333-7.
34. van der Mast BJ, Balk AH. Effect of HLA-DR-shared blood transfusion on the clinical outcome of heart transplantation. Transplantation 1997; 63: 1514-19.
35. Fernandez FG, Jaramillo A, Ewald G, et al. Blood transfusions decrease the incidence of acute rejection in cardiac allograft recipients. J Heart Lung Transplant 2005; 24(Suppl. 7): S255-61.
36. Stratta RJ, Taylor RJ, Sindhi R, et al. Is there a transfusion effect in combined pancreas-kidney transplantation? Transplant Proc 1995; 27: 3096.
37. Waanders MM, Roelen DL, de Fijter JW, et al. Protocolled blood transfusions in recipients of a simultaneous pancreas-kidney transplant reduce severe acute graft rejection. Transplantation 2008; 85: 1668-70.
38. Koneru B, Harrison D, Rizwan M, et al. Blood transfusions in liver recipients: A conundrum or a clear benefit in the cyclosporine/ tacrolimus era? Transplantation 1997; 63: 1587-90.
39. Parker BM, Irefin SA, Sabharwal V, et al. Leukocyte reduction during orthotopic liver transplantation and postoperative outcome: A pilot study. J Clin Anesth 2004; 16: 18-24.
40. Golshayan D, Buhler L, Lechler RI, Pascual M. From current immunosuppressive strategies to clinical tolerance of allografts. Transplant Int 2007; 20: 12-24.
41. Puppo F, Ghio M, Contini P, Mazzei C, Indiveri F. Fas, Fas ligand, and transfusion immunomodulation. Transfusion 2001; 41: 416-18.
42. Rammensee HG. Veto function in vitro and in vivo. Int Rev Immunol 1989; 4: 175-91.
43. van Parijs L, Abbas AK. Role of Fas-mediated cell death in the regulation of immune responses. Curr Opin Immunol 1996; 8: 355-61.
44. Lechler R, Chai JG, Marelli-Berg F, Lombardi G. The contributions of T-cell anergy to peripheral T-cell tolerance. Immunology 2001; 103: 262-9.
45. Schwartz RH. T cell anergy. Sci Am 1993; 269: 62-71.
46. Powell JD. The induction and maintenance of T cell anergy. Clin Immunol 2006; 120: 239-46.
47. Alegre ML, Najafian N. Costimulatory molecules as targets for the induction of transplantation tolerance. Curr Mol Med 2006; 6: 843-57.
48. Sakaguchi S. Naturally arising CD4+ regulatory T cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol 2004; 22: 531-62.
49. Hutchinson IV. Suppressor T cells in allogeneic models. Transplantation 1986; 41: 547-55.
50. Quigley RL, Wood KJ, Morris PJ. Transfusion induces blood donor-specific suppressor cells. J Immunol 1989; 142: 463-70.
51. Jiang S, Lechler RI, He XS, Huang JF. Regulatory T cells and transplantation tolerance. Hum Immunol 2006; 67: 765-76.
52. Claas FHJ, de Koster HS, Lagaaij EL, van Rood JJ. A molecular mechanism of T cell downregulation by blood transfusion. Exp Nephrol 1993; 1: 134-8.
53. Waanders MM, Roelen DL, Brand A, Claas FH. The putative mechanism of the immunomodulating effect of HLA-DR shared allogeneic blood transfusions on the alloimmune response. Transfus Med Rev 2005; 19: 281-7.
54. Roelen DL, van Bree S, van Hulst P, van Beelen E, Claas FHJ. Regulatory functions of human CD4(+) T cells recognizing allopeptides in the context of self-HLA class II. Hum Immunol 2002; 63: 902-11.
55. Claas FHJ, Roelen DL, van Rood JJ, Brand A. Modulation of the alloimmune response by blood transfusions. Transfus Clin Biol 2001; 8: 315-17.
56. Steinbrink K, Jonuleit H, Wölfl M, Knop J, Enk A. Induction of tolerance by interleukin-10-treated human dendritic cells. J Invest Dermatol 1997; 108: 231.
57. Amato A, Pescatori M. Perioperative blood transfusions for the recurrence of colorectal cancer. Cochrane Database Syst Rev 2006; (1): CD005033.
58. Houbiers JG, Brand A, van de Watering LM, et al. Randomised controlled trial comparing transfusion of leucocyte-depleted or buffy-coat-depleted blood in surgery for colorectal cancer. Lancet 1994; 344: 573-8.
59. van de Watering LM, Brand A, Houbiers JG, et al. Perioperative blood transfusions, with or without allogeneic leucocytes, relate to survival, not to cancer recurrence. Br J Surg 2001; 88: 267-72.
60. Natali PG, Bigotti A, Cavaliere R, Nicotra MR, Ferrone S. Phenotyping of lesions of melanocyte origin with monoclonal antibodies to melanoma-associated antigens and to HLA antigens. J Natl Cancer Inst 1984; 73: 13-24.
61. Momburg F, Degener T, Bacchus E, et al. Loss of HLA-A,B,C and de novo expression of HLA-D in colorectal cancer. Int J Cancer 1986; 37: 179-84.
62. Heiss MM, Mempel W, Jauch KW, et al. Beneficial effect of autologous blood transfusion on infectious complications after colorectal cancer surgery. Lancet 1993; 342: 1328-33.
63. Braga M, Vignali A, Radaelli G, Gianotti L, Di Carlo V. Association between perioperative blood transfusion and postoperative infection in patients having elective operations for gastrointestinal cancer. Eur J Surg 1992; 158: 531-6.
64. Hill GE, Frawley WH, Griffith KE, Forestner JE, Minei JP. Allogeneic blood transfusion increases the risk of postoperative bacterial infection: A meta-analysis. J Trauma 2003; 54: 908-14.
65. Tartter PI, Driefuss RM, Malon AM, Heimann TM, Aufses AH. Relationship of postoperative septic complications and blood transfusions in patients with Crohn's disease. Am J Surg 1988; 155: 43-8.
66. van de Watering LM, Hermans J, Houbiers JG, et al. Beneficial effects of leukocyte depletion of transfused blood on postoperative complications in patients undergoing cardiac surgery: A randomized clinical trial. Circulation 1998; 97: 562-8.
67. Wallis JP, Chapman CE, Orr KE, Clark SC, Forty JR. Effect of WBC reduction of transfused RBCs on postoperative infection rates in cardiac surgery. Transfusion 2002; 42: 1127-34.
68. Vamvakas EC. Possible mechanisms of allogeneic blood transfusion-associated postoperative infection. Transfus Med Rev 2002; 16: 144-60.
69. Johnston P, Wynn-Jones H, Chakravarty D, Boyle A, Parker MJ. Is perioperative blood transfusion a risk factor for mortality or infection after hip fracture? J Orthop Trauma 2006; 20: 675-9.
70. Jensen LS, Andersen AJ, Christiansen PM, et al. Postoperative infection and natural killer cell function following blood transfusion in patients undergoing elective colorectal surgery. Br J Surg 1992; 79: 513-16.
71. Jensen LS, Kissmeyer-Nielsen P, Wolff B, Qvist N. Randomised comparison of leucocyte-depleted versus buffy-coat-poor blood transfusion and complications after colorectal surgery. Lancet 1996; 348: 841-5.
72. Tartter PI, Mohandas K, Azar P, et al. Randomized trial comparing packed red cell blood transfusion with and without leukocyte depletion for gastrointestinal surgery. Am J Surg 1998; 176: 462-6.
73. Titlestad IL, Ebbesen LS, Ainsworth AP, et al. Leukocyte-depletion of blood components does not significantly reduce the risk of infectious complications. Results of a double-blinded, randomized study. Int J Colorectal Dis 2001; 16: 147-53.
74. Bilgin YM, van de Watering LM, Eijsman L, et al. Double-blind, randomized controlled trial on the effect of leukocyte-depleted erythrocyte transfusions in cardiac valve surgery. Circulation 2004; 109: 2755-60.
75. van Hilten JA, van de Watering LM, van Bockel JH, et al. Effects of transfusion with red cells filtered to remove leucocytes: Randomised controlled trial in patients undergoing major surgery. BMJ 2004; 328: 1281.
76. Blumberg N, Zhao H, Wang H, et al. The intention-to-treat principle in clinical trials and meta-analyses of leukoreduced blood transfusions in surgical patients. Transfusion 2007; 47: 573-81.
77. Vamvakas EC. Deleterious clinical effects of transfusion immunomodulation: Proven beyond a reasonable doubt. Transfusion 2006; 46: 492-4.
78. Kunz R, Guyatt G. Which patients to include in the analysis? Transfusion 2006; 46: 881-4.
79. Blumberg N. Deleterious clinical effects of transfusion immunomodulation: Proven beyond a reasonable doubt. Transfusion 2005; 45(Suppl. 2): 33S-9S.
80. Vamvakas EC. Meta-analysis of randomized controlled trials investigating the risk of postoperative infection in association with white blood cell-containing allogeneic blood transfusion: The effects of the type of transfused red blood cell product and surgical setting. Transfus Med Rev 2002; 16: 304-14.
81. Vamvakas EC. White-blood-cell-containing allogeneic blood transfusion, postoperative infection and mortality: A meta-analysis of observational 'before-and-after' studies. Vox Sang 2004; 86: 111-19.
82. Vamvakas EC. Transfusion-associated cancer recurrence and postoperative infection: Meta-analysis of randomized, controlled clinical trials. Transfusion 1996; 36: 175-86.
83. McAlister FA, Clark HD, Wells PS, Laupacis A. Perioperative allogeneic blood transfusion does not cause adverse sequelae in patients with cancer: A meta-analysis of unconfounded studies. Br J Surg 1998; 85: 171-8.
84. Fergusson D, Khanna MP, Tinmouth A, Hébert PC. Transfusion of leukoreduced red blood cells may decrease postoperative infections: Two meta-analyses of randomized controlled trials. Can J Anaesth 2004; 51: 417-24.
85. Vamvakas EC. White-blood-cell-containing allogeneic blood transfusion and postoperative infection or mortality: An updated meta-analysis. Vox Sang 2007; 92: 224-32.
86. Vamvakas EC, Blajchman MA. A proposal for an individual patient data based meta-analysis of randomized controlled trials of allogeneic transfusion and postoperative bacterial infection. Transfus Med Rev 1997; 11: 180-94.
87. Silliman CC, Thurman GW, Ambruso DR. Stored blood components contain agents that prime the neutrophil NADPH oxidase through the platelet-activating-factor receptor. Vox Sang 1992; 63: 133-6.
88. Zallen G, Offner PJ, Moore EE, et al. Age of transfused blood is an independent risk factor for postinjury multiple organ failure. Am J Surg 1999; 178: 570-2.
89. Johnson JL, Moore EE, Gonzalez RJ, et al. Alteration of the postinjury hyperinflammatory response by means of resuscitation with a red cell substitute. J Trauma 2003; 54: 133-9.
90. Muylle L, Joos M, Wouters E, De BR, Peetermans ME. Increased tumor necrosis factor alpha (TNF alpha), interleukin 1, and interleukin 6 (IL-6) levels in the plasma of stored platelet concentrates: relationship between TNF alpha and IL-6 levels and febrile transfusion reactions. Transfusion 1993; 33: 195-9.
91. Wadhwa M, Seghatchian MJ, Dilger P, Contreras M, Thorpe R. Cytokine accumulation in stored red cell concentrates: Effect of buffy-coat removal and leucoreduction. Transfus Sci 2000; 23: 7-16.
92. Williamson LM, Murphy MF, Llewelyn C, et al. Leucocyte-depleted blood in prevention of postoperative infections following elective orthopaedic and cardiac procedures. Vox Sang 2002; 83(Suppl. 1): 457-60.
93. Baron JF, Gourdin M, Bertrand M, et al. The effect of universal leukodepletion of packed red blood cells on postoperative infections in high-risk patients undergoing abdominal aortic surgery. Anesth Analg 2002; 94: 529-37.
94. Blumberg N, Heal JM, Cowles JW, et al. Leukocyte-reduced transfusions in cardiac surgery results of an implementation trial. Am J Clin Pathol 2002; 118: 376-81.
95. Hébert PC, Fergusson D, Blajchman MA, et al. Clinical outcomes following institution of the Canadian universal leukoreduction program for red blood cell transfusions. JAMA 2003; 289: 1941-9.
96. Sauaia A, Moore FA, Moore EE, et al. Early predictors of postinjury multiple organ failure. Arch Surg 1994; 129: 39-45.
97. Tran DD, Van Onselen EB, Wensink AJ, Cuesta MA. Factors related to multiple organ system failure and mortality in a surgical intensive care unit. Nephrol Dial Transplant 1994; 9(Suppl. 4): 172-8.
98. Vincent JL, Baron JF, Reinhart K, et al. Anemia and blood transfusion in critically ill patients. JAMA 2002; 288: 1499-507.
99. Maetani S, Nishikawa T, Tobe T, Hirakawa A. Role of blood transfusion in organ system failure following major abdominal surgery. Ann Surg 1986; 203: 275-81.
100. Bracey AW, Radovancevic R, Nussmeier NA, et al. Leukocyte-reduced blood in open-heart surgery patients: Effects on outcome. Transfusion 2002; 42(Suppl.): 5S.
101. Boshkov LK, Furnary A, Morris C, et al. Prestorage leukoreduction of red cells in elective cardiac surgery: Results of a double-blind randomized controlled trial. Blood 2004; 104: 112a.
102. Nathens AB, Nester TA, Rubenfeld GD, Nirula R, Gernsheimer TB. The effects of leukoreduced blood transfusion on infection risk following injury: A randomized controlled trial. Shock 2006; 26: 342-7.
103. Nielsen HJ, Hammer JH, Krarup AL, et al. Prestorage leukocyte filtration may reduce leukocyte-derived bioactive substance accumulation in patients operated for burn trauma. Burns 1999; 25: 162-70.
104. Dzik WH, Anderson JK, O'Neill EM, et al. A prospective, randomized clinical trial of universal WBC reduction. Transfusion 2002; 42: 1114-22.
105. Busch OR, Hop WC, Hoynck van Papendrecht MA, Marquet RL, Jeekel J. Blood transfusions and prognosis in colorectal cancer. N Engl J Med 1993; 328: 1372-6.
106. Farrer A, Spark JI, Scott DJ. Autologous blood transfusion: The benefits to the patient undergoing abdominal aortic aneurysm repair. J Vasc Nurs 1997; 15: 111-15.
107. Wong JC, Torella F, Haynes SL, et al. Autologous versus allogeneic transfusion in aortic surgery: A multicenter randomized clinical trial. Ann Surg 2002; 235: 145-51.
108. Vamvakas ECWB. C-containing allogeneic blood transfusion and mortality: a meta-analysis of randomized controlled trials. Transfusion 2003; 43: 963-73.
109. Fast LD. Recipient elimination of allogeneic lymphoid cells: Donor CD4(+) cells are effective alloantigen-presenting cells. Blood 2000; 96: 1144-9.